Inhibikase Therapeutics Inc (IKT)

$1.68 -0.03 (-1.75%)
Market Cap 128.55M
Revenue (ttm) 0.00
Net Income (ttm) -27.52M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 220,400
Avg Vol 492,596
Day's Range N/A - N/A
Shares Out 75.18M
Stochastic %K 9%
Beta 0.84
Analysts Strong Sell
Price Target $6.60

Company Profile

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia....

Industry: Biotechnology
Sector: Healthcare
Phone: 678 392 3419
Address:
3350 Riverwood Parkway SE, Suite 1900, Atlanta, United States
PSM_EmpowerTrading
PSM_EmpowerTrading Jan. 13 at 2:24 PM
🌅 Watchlist part 3 ✅ $UAVS low $1.75 support, if above $2.00, potential to $2.40 / $2.70 High $1.98, up 133% from recent swing post , 🥳CONGRATS if you got in during the swing accumulation phase below $0.85 ✅ $UP low $1.00 support, if above $1.35, potential to $1.50 / $1.70 ✅ $WWR low $1.00 support, if above $1.50, potential to $1.70 / $1.80 🚨 Not ideal for swing accumulation at current prices ✅ Ideal long entry near low current support 🎯 Ideal stop loss below current support 🚨 Avoid chasing long into strength near resistance ⏳⏳ $YCBD $IKT still in swing accumulation phase 🎯🎯 Goal is GR💰💰N, not GR🔥🔥D
0 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading Jan. 9 at 8:18 PM
⌛️⏳️Potential swing ideas 💡 ✅️ $IKT company focuses on developing therapies for neurodegenerative disorders, especially Parkinson's disease and related conditions, upcoming catalyst: phase 3 study for Pulmonary arterial hypertension expected to begin Q1 2026, HC Wainwright price target 8, Cantor Fitzgeral price target 4 ✅️ $LUNG company focuses on minimally invasive treatments for chronic obstructive pulmonary disease (COPD) and severe emphysema, D. Boral Capital price target $14, Stifel Nicolaus buy rating, Lake Street price target 4, Canaccord Genuity buy rating ✅️ $XELB company focuses on medica and consumer products, designing, licensing, marketing and selling branded products, band portfolio includes Halston, Judity Ripka, C Wonder, TowerHill by Christie Brinkley, Longaberger and others across apparel, footwear, accessories, home goods, CEO Robert D'Loren and Director Mark DiSanto recently purchased shares, Noble Financial buy rating
1 · Reply
HeWhoLaughs
HeWhoLaughs Jan. 9 at 7:27 PM
$IKT $SPY $GPUS You bears are doomed
0 · Reply
HeWhoLaughs
HeWhoLaughs Jan. 9 at 4:06 PM
$IKT Got you HC $SPY
0 · Reply
HeWhoLaughs
HeWhoLaughs Jan. 9 at 3:49 PM
$IKT Another man’s trash is….
0 · Reply
BiotechJedi1728
BiotechJedi1728 Jan. 9 at 3:47 AM
$IKT WTAF. If this executive thing is true, not happy.
1 · Reply
BillyTheKid62
BillyTheKid62 Jan. 9 at 2:39 AM
$IKT I'd rather have a bad case of hemroids than one this stock . Wait I do have a bad case of hemroids but owning this stock I almost forgot about them .
0 · Reply
BillyTheKid62
BillyTheKid62 Jan. 8 at 10:34 PM
$IKT This stock sucks goats milk !!
0 · Reply
little_jackie
little_jackie Jan. 8 at 8:05 PM
$IKT You guys really thought @BiotechJedi1728 was going to lead you the right way here?
0 · Reply
Mjf04288
Mjf04288 Jan. 8 at 7:34 PM
$IKT $2.00 didn’t last long
0 · Reply
Latest News on IKT
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

Nov 20, 2025, 9:54 PM EST - 7 weeks ago

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Nov 20, 2025, 4:12 PM EST - 7 weeks ago

Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension

Nov 20, 2025, 4:01 PM EST - 7 weeks ago

Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension

Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity

Nov 14, 2025, 4:01 PM EST - 2 months ago

Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer

Aug 19, 2025, 8:00 AM EDT - 5 months ago

Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer

Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity

Aug 14, 2025, 4:50 PM EDT - 5 months ago

Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity

May 14, 2025, 4:05 PM EDT - 8 months ago

Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer

Apr 14, 2025, 8:00 AM EDT - 9 months ago

Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer

Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity

Mar 27, 2025, 4:01 PM EDT - 10 months ago

Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity

Inhibikase Announces Expansion of Senior Leadership Team

Feb 24, 2025, 8:00 AM EST - 11 months ago

Inhibikase Announces Expansion of Senior Leadership Team

Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth

Feb 18, 2025, 8:00 AM EST - 11 months ago

Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth

Inhibikase Therapeutics stops Parkinson's drug development as it fails to show benefits in study

Jan 29, 2025, 6:30 PM EST - 1 year ago

Inhibikase Therapeutics stops Parkinson's drug development as it fails to show benefits in study

Inhibikase: Potential To Improve Current Treatment Options For PAH Patients

Nov 19, 2024, 1:32 PM EST - 1 year ago

Inhibikase: Potential To Improve Current Treatment Options For PAH Patients

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity

Nov 14, 2024, 8:37 AM EST - 1 year ago

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension

Oct 21, 2024, 9:05 AM EDT - 1 year ago

Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension

Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension

Oct 9, 2024, 9:18 AM EDT - 1 year ago

Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension

Inhibikase Therapeutics, Inc. (IKT) Q2 2024 Earnings Call Transcript

Aug 15, 2024, 6:13 PM EDT - 1 year ago

Inhibikase Therapeutics, Inc. (IKT) Q2 2024 Earnings Call Transcript

Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity

Aug 14, 2024, 4:25 PM EDT - 1 year ago

Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity

Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

Aug 7, 2024, 8:00 AM EDT - 1 year ago

Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201' Trial Evaluating Risvodetinib in Untreated Parkinson's Disease

Jun 17, 2024, 8:05 AM EDT - 1 year ago

Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201' Trial Evaluating Risvodetinib in Untreated Parkinson's Disease

Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs

Jun 5, 2024, 8:05 AM EDT - 1 year ago

Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs

Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million

May 20, 2024, 8:01 AM EDT - 1 year ago

Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million

Inhibikase Therapeutics, Inc. (IKT) Q1 2024 Earnings Call Transcript

May 17, 2024, 9:57 PM EDT - 1 year ago

Inhibikase Therapeutics, Inc. (IKT) Q1 2024 Earnings Call Transcript

Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity

May 15, 2024, 8:00 PM EDT - 1 year ago

Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity

Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement

May 15, 2024, 8:45 AM EDT - 1 year ago

Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement

Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension

May 9, 2024, 8:00 AM EDT - 1 year ago

Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

Apr 18, 2024, 4:30 PM EDT - 1 year ago

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

Apr 3, 2024, 8:05 AM EDT - 1 year ago

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

Inhibikase Therapeutics, Inc. (IKT) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 5:13 PM EDT - 1 year ago

Inhibikase Therapeutics, Inc. (IKT) Q4 2023 Earnings Call Transcript

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity

Mar 27, 2024, 4:15 PM EDT - 1 year ago

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Mar 7, 2024, 8:30 AM EST - 2 years ago

Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro

Feb 28, 2024, 4:05 PM EST - 2 years ago

Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro

Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers

Feb 7, 2024, 7:55 AM EST - 2 years ago

Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers

Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib

Jan 29, 2024, 9:05 AM EST - 2 years ago

Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib

Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli

Jan 16, 2024, 4:05 PM EST - 2 years ago

Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli

Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro

Dec 4, 2023, 8:35 AM EST - 2 years ago

Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro

Inhibikase Therapeutics, Inc. (IKT) Q2 2023 Earnings Call Transcript

Nov 15, 2023, 5:38 PM EST - 2 years ago

Inhibikase Therapeutics, Inc. (IKT) Q2 2023 Earnings Call Transcript

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity

Nov 14, 2023, 4:30 PM EST - 2 years ago

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity

Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023

Nov 7, 2023, 9:28 AM EST - 2 years ago

Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023

Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson's Disease and Provides Update on Ongoing Enrollment

Oct 16, 2023, 7:00 AM EDT - 2 years ago

Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson's Disease and Provides Update on Ongoing Enrollment

Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy

Oct 4, 2023, 8:30 AM EDT - 2 years ago

Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy

Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib

Aug 24, 2023, 8:30 AM EDT - 2 years ago

Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib

Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders

Aug 22, 2023, 8:05 AM EDT - 2 years ago

Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders

Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib

Aug 21, 2023, 8:30 AM EDT - 2 years ago

Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib

Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Pro

Aug 17, 2023, 8:30 AM EDT - 2 years ago

Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Pro

Inhibikase Therapeutics to Report Second Quarter Financial Results on August 14, 2023

Aug 7, 2023, 8:05 AM EDT - 2 years ago

Inhibikase Therapeutics to Report Second Quarter Financial Results on August 14, 2023

Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements

Jul 17, 2023, 4:05 PM EDT - 2 years ago

Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements

Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split

Jun 29, 2023, 9:29 AM EDT - 2 years ago

Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split

Inhibikase Therapeutics Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study

Jun 22, 2023, 8:05 AM EDT - 2 years ago

Inhibikase Therapeutics Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study

PSM_EmpowerTrading
PSM_EmpowerTrading Jan. 13 at 2:24 PM
🌅 Watchlist part 3 ✅ $UAVS low $1.75 support, if above $2.00, potential to $2.40 / $2.70 High $1.98, up 133% from recent swing post , 🥳CONGRATS if you got in during the swing accumulation phase below $0.85 ✅ $UP low $1.00 support, if above $1.35, potential to $1.50 / $1.70 ✅ $WWR low $1.00 support, if above $1.50, potential to $1.70 / $1.80 🚨 Not ideal for swing accumulation at current prices ✅ Ideal long entry near low current support 🎯 Ideal stop loss below current support 🚨 Avoid chasing long into strength near resistance ⏳⏳ $YCBD $IKT still in swing accumulation phase 🎯🎯 Goal is GR💰💰N, not GR🔥🔥D
0 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading Jan. 9 at 8:18 PM
⌛️⏳️Potential swing ideas 💡 ✅️ $IKT company focuses on developing therapies for neurodegenerative disorders, especially Parkinson's disease and related conditions, upcoming catalyst: phase 3 study for Pulmonary arterial hypertension expected to begin Q1 2026, HC Wainwright price target 8, Cantor Fitzgeral price target 4 ✅️ $LUNG company focuses on minimally invasive treatments for chronic obstructive pulmonary disease (COPD) and severe emphysema, D. Boral Capital price target $14, Stifel Nicolaus buy rating, Lake Street price target 4, Canaccord Genuity buy rating ✅️ $XELB company focuses on medica and consumer products, designing, licensing, marketing and selling branded products, band portfolio includes Halston, Judity Ripka, C Wonder, TowerHill by Christie Brinkley, Longaberger and others across apparel, footwear, accessories, home goods, CEO Robert D'Loren and Director Mark DiSanto recently purchased shares, Noble Financial buy rating
1 · Reply
HeWhoLaughs
HeWhoLaughs Jan. 9 at 7:27 PM
$IKT $SPY $GPUS You bears are doomed
0 · Reply
HeWhoLaughs
HeWhoLaughs Jan. 9 at 4:06 PM
$IKT Got you HC $SPY
0 · Reply
HeWhoLaughs
HeWhoLaughs Jan. 9 at 3:49 PM
$IKT Another man’s trash is….
0 · Reply
BiotechJedi1728
BiotechJedi1728 Jan. 9 at 3:47 AM
$IKT WTAF. If this executive thing is true, not happy.
1 · Reply
BillyTheKid62
BillyTheKid62 Jan. 9 at 2:39 AM
$IKT I'd rather have a bad case of hemroids than one this stock . Wait I do have a bad case of hemroids but owning this stock I almost forgot about them .
0 · Reply
BillyTheKid62
BillyTheKid62 Jan. 8 at 10:34 PM
$IKT This stock sucks goats milk !!
0 · Reply
little_jackie
little_jackie Jan. 8 at 8:05 PM
$IKT You guys really thought @BiotechJedi1728 was going to lead you the right way here?
0 · Reply
Mjf04288
Mjf04288 Jan. 8 at 7:34 PM
$IKT $2.00 didn’t last long
0 · Reply
TJC1791
TJC1791 Jan. 7 at 10:43 PM
$IKT just a lazy 7m shares handed out to 3 execs today, inc 5m for the CEO. 😤😤
0 · Reply
BillyTheKid62
BillyTheKid62 Jan. 7 at 8:49 PM
$IKT Parties over here . Fun while it lasted . Not !
0 · Reply
Mjf04288
Mjf04288 Jan. 5 at 8:53 PM
$IKT
0 · Reply
NightStatic
NightStatic Jan. 3 at 3:38 AM
$IKT
0 · Reply
Alien1980
Alien1980 Jan. 2 at 2:17 PM
$IKT showing signs of continued momentum again this week. Price target has been set to 8 bux.. 👽👽
0 · Reply
TJC1791
TJC1791 Jan. 1 at 1:55 AM
$IKT https://radientanalytics.com/firm/adv/trails-edge-capital-partners-lp-335659
0 · Reply
TJC1791
TJC1791 Jan. 1 at 1:53 AM
$IKT https://ir.stockpr.com/inhibikase/sec-filings-email/content/0001493152-25-029834/primary_doc.html
0 · Reply
Major_Bagholder
Major_Bagholder Dec. 26 at 8:13 PM
$IKT Offering soon?
3 · Reply
HellenicRenegade
HellenicRenegade Dec. 26 at 5:38 PM
$IKT what time does trading stop today
1 · Reply
BiotechJedi1728
BiotechJedi1728 Dec. 26 at 4:15 PM
$IKT This cracks $3 by February. Get in losers. Time to win! 💵
2 · Reply
OpenOutcrier
OpenOutcrier Dec. 26 at 1:55 PM
$IKT H.C. Wainwright Assumes Inhibikase Therapeutics Inc (IKT) at Buy, $8 PT
0 · Reply
BrewingBoss
BrewingBoss Dec. 26 at 1:12 PM
$IKT Risk appetite is present but conditioned on validation. Operating rhythm should stabilize as learning cycles compress. Clear execution would attract broader institutional participation. The forward path ultimately depends on disciplined delivery.
0 · Reply